DOI 10.1158/1078-0432.ccr-25-4896
Phase I Study of Rogocekib in Patients with Advanced, Relapsed, or Refractory Malignant Solid Tumors.
Аннотация
PURPOSE: Aberrant splicing plays a significant role in cancer progression, yet targeted treatments are lacking. Rogocekib (developmental name CTX-712) is a potent oral inhibitor of CDC2-like kinase that targets RNA splicing. This phase I study aimed to evaluate the maximum tolerated dose (MTD), dose-limiting toxicity (DLT), safety, tolerability, pharmacokinetics (PK)/pharmacodynamics (PD) profiles, preliminary efficacy, and the recommended dose of rogocekib in patients with advanced solid tumors.
PATIENTS AND
METHODS
The dose escalation started with an accelerated titration phase and then transitioned to a 3 + 3 design at doses ranging from 10 to 175 mg, administered twice weekly. For dose expansion, 105 mg twice weekly, 70 mg twice weekly, and 105 mg once weekly were investigated.
RESULTS
In total, 46 patients with solid tumors were administered rogocekib. The MTD was determined to be 140 mg twice weekly. DLTs were observed in one patient at 140 mg twice weekly (platelet count decreased and hypokalemia) and in one patient at 175 mg twice weekly (dehydration). Common related adverse events included nausea, vomiting, and diarrhea. Two treatment-related deaths were observed. PK analysis showed a dose-dependent increase in systemic exposure to rogocekib. PD analysis of two markers (THAP9-AS1 and S6K) showed target engagement of rogocekib. A partial response was observed in 6.5% of patients, all with ovarian cancer (n = 3).
CONCLUSIONS
Although most toxicities were manageable, two treatment-related deaths were observed, underscoring the need for vigilant safety monitoring. Overall, rogocekib demonstrated evidence of target engagement in most patients with solid tumors and preliminary antitumor activity, warranting further clinical investigation.
Предметные рубрики MeSH
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.